Compugen LTD revenue

Compugen LTD's revenue was $72.8m in fiscal 2025, up 161.1% on the year before. Since fiscal 2009 ($250,000) it has grown at a compound 54.7% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Compugen LTD: revenue history, annual
Fiscal year	2009Dec 2009	2010Dec 2010	2012Dec 2012	2013Dec 2013	2014Dec 2014	2015Dec 2015	2016Dec 2016	2018Dec 2018	2020Dec 2020	2021Dec 2021	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025
Revenue	0	1	0	4	12	9	1	18	2	6	8	33	28	73
Growth on the year before	—	+346.0%	−78.3%	+>999%	+248.5%	−25.0%	−92.3%	+>999%	−88.8%	+200.0%	+25.0%	+346.1%	−16.7%	+161.1%
Gross profit	0	1	0	1	9	8	0	17	2	5	7	31	20	64
Gross margin	100.0%	79.9%	16.9%	29.3%	73.0%	82.4%	68.7%	94.2%	97.0%	88.7%	87.0%	94.0%	71.5%	87.3%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Compugen LTD	$72.8m	161.1%	302.6%
Viridian Therapeutics, Inc.\de	$71.1m	23220.3%	264.4%
Wave Life Sciences, Inc.	$70.9m	202.3%	20.7%
Assembly Biosciences, Inc.	$74.8m	125.1%	-3.3%
Recursion Pharmaceuticals, Inc.	$68.2m	56.2%	12.9%
Cytokinetics Inc	$67.7m	-21.1%	89.5%

Compare with peers

Head to head: CGEN vs VRDN CGEN vs WVE ASMB vs CGEN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Compugen LTD's SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Compugen LTD.